A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

September 20, 2022

Study Completion Date

September 20, 2022

Conditions

Healthy Participants

Interventions

DRUG

AZD5462

Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

DRUG

Placebo

Participants will receive Placebo matched to AZD5462.

Trial Locations (1)

Research Site, Glendale